Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aditxt, Inc. - Common Stock (NQ:ADTX)

1.020 -0.010 (-0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aditxt, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer
Via Investor Brand Network
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy
Via Investor Brand Network
Research Explains Why MS Patients Benefit from Stem Cell Transplants
Via Investor Brand Network
Why Food Allergies May Be Increasing
Via Investor Brand Network
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
From Aditxt, Inc.
Via Business Wire
Study Finds Organ Transplant Recipients Undervaccinated
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on! 
Via InvestorPlace
Consuming Too Much Salt May Trigger Autoimmune Illnesses
Via Investor Brand Network
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms
Via Investor Brand Network
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
From Aditxt, Inc.
Via Business Wire
Food Allergies Worsen Cost of Living for Impacted Individuals
Via Investor Brand Network
Topics Economy
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine
Via Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies
Via Investor Brand Network
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
From Aditxt, Inc.
Via Business Wire
Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
Via Investor Brand Network
Researchers Look to AI to Improve Organ Transplant Processes
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports
Via Investor Brand Network
Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Genes That Saved People from Bubonic Plague Linked to Autoimmune Conditions Today
Via Investor Brand Network
Research Finds That Stem Cells Reduce Lung Transplant Rejection Rates
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 96 stocks hit new 52-week lows. 
Via Benzinga
Study Finds Livers with a Cumulative Age of 100 Years
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
Via Investor Brand Network
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
Allergies: How They Occur and Why They Sometimes Disappear
Via Investor Brand Network
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.